These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 36307868)

  • 1. Reemergence of pathogenic, autoantibody-producing B cell clones in myasthenia gravis following B cell depletion therapy.
    Fichtner ML; Hoehn KB; Ford EE; Mane-Damas M; Oh S; Waters P; Payne AS; Smith ML; Watson CT; Losen M; Martinez-Martinez P; Nowak RJ; Kleinstein SH; O'Connor KC
    Acta Neuropathol Commun; 2022 Oct; 10(1):154. PubMed ID: 36307868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autoantibody-producing plasmablasts after B cell depletion identified in muscle-specific kinase myasthenia gravis.
    Stathopoulos P; Kumar A; Nowak RJ; O'Connor KC
    JCI Insight; 2017 Sep; 2(17):. PubMed ID: 28878127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of pathogenic monoclonal autoantibodies derived from muscle-specific kinase myasthenia gravis patients.
    Takata K; Stathopoulos P; Cao M; Mané-Damas M; Fichtner ML; Benotti ES; Jacobson L; Waters P; Irani SR; Martinez-Martinez P; Beeson D; Losen M; Vincent A; Nowak RJ; O'Connor KC
    JCI Insight; 2019 Jun; 4(12):. PubMed ID: 31217355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunotherapies in MuSK-positive Myasthenia Gravis; an IgG4 antibody-mediated disease.
    Vakrakou AG; Karachaliou E; Chroni E; Zouvelou V; Tzanetakos D; Salakou S; Papadopoulou M; Tzartos S; Voumvourakis K; Kilidireas C; Giannopoulos S; Tsivgoulis G; Tzartos J
    Front Immunol; 2023; 14():1212757. PubMed ID: 37564637
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanisms underlying B cell immune dysregulation and autoantibody production in MuSK myasthenia gravis.
    Stathopoulos P; Kumar A; Heiden JAV; Pascual-Goñi E; Nowak RJ; O'Connor KC
    Ann N Y Acad Sci; 2018 Jan; 1412(1):154-165. PubMed ID: 29381221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autoimmune Pathology in Myasthenia Gravis Disease Subtypes Is Governed by Divergent Mechanisms of Immunopathology.
    Fichtner ML; Jiang R; Bourke A; Nowak RJ; O'Connor KC
    Front Immunol; 2020; 11():776. PubMed ID: 32547535
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Lasting Rituximab-Induced Reduction of Specific-But Not Total-IgG4 in MuSK-Positive Myasthenia Gravis.
    Marino M; Basile U; Spagni G; Napodano C; Iorio R; Gulli F; Todi L; Provenzano C; Bartoccioni E; Evoli A
    Front Immunol; 2020; 11():613. PubMed ID: 32431692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-cell repertoire tracing identifies rituximab-resistant B cells during myasthenia gravis relapses.
    Jiang R; Fichtner ML; Hoehn KB; Pham MC; Stathopoulos P; Nowak RJ; Kleinstein SH; O'Connor KC
    JCI Insight; 2020 Jul; 5(14):. PubMed ID: 32573488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between musk antibody concentrations and the myasthenia gravis composite score in 3 patients: A marker of relapse?
    Triplett JD; Hardy TA; Riminton DS; Chu SYK; Reddel SW
    Muscle Nerve; 2019 Sep; 60(3):307-311. PubMed ID: 31177576
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stable expression of human muscle-specific kinase in HEp-2 M4 cells for automatic immunofluorescence diagnostics of myasthenia gravis.
    George S; Paulick S; Knütter I; Röber N; Hiemann R; Roggenbuck D; Conrad K; Küpper JH
    PLoS One; 2014; 9(1):e83924. PubMed ID: 24416182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IgG4 autoantibodies against muscle-specific kinase undergo Fab-arm exchange in myasthenia gravis patients.
    Koneczny I; Stevens JA; De Rosa A; Huda S; Huijbers MG; Saxena A; Maestri M; Lazaridis K; Zisimopoulou P; Tzartos S; Verschuuren J; van der Maarel SM; van Damme P; De Baets MH; Molenaar PC; Vincent A; Ricciardi R; Martinez-Martinez P; Losen M
    J Autoimmun; 2017 Feb; 77():104-115. PubMed ID: 27965060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MuSK myasthenia gravis IgG4 disrupts the interaction of LRP4 with MuSK but both IgG4 and IgG1-3 can disperse preformed agrin-independent AChR clusters.
    Koneczny I; Cossins J; Waters P; Beeson D; Vincent A
    PLoS One; 2013; 8(11):e80695. PubMed ID: 24244707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antigen specific B cells in myasthenia gravis patients.
    Takata K; Kinoshita M; Mochizuki H; Okuno T
    Immunol Med; 2020 Jun; 43(2):65-71. PubMed ID: 32046601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MuSK myasthenia gravis monoclonal antibodies: Valency dictates pathogenicity.
    Huijbers MG; Vergoossen DL; Fillié-Grijpma YE; van Es IE; Koning MT; Slot LM; Veelken H; Plomp JJ; van der Maarel SM; Verschuuren JJ
    Neurol Neuroimmunol Neuroinflamm; 2019 May; 6(3):e547. PubMed ID: 30882021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis.
    Leite MI; Jacob S; Viegas S; Cossins J; Clover L; Morgan BP; Beeson D; Willcox N; Vincent A
    Brain; 2008 Jul; 131(Pt 7):1940-52. PubMed ID: 18515870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short- and Long-Lived Autoantibody-Secreting Cells in Autoimmune Neurological Disorders.
    Zografou C; Vakrakou AG; Stathopoulos P
    Front Immunol; 2021; 12():686466. PubMed ID: 34220839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of muscle-specific tyrosine kinase (MuSK) and mystery of MuSK myasthenia gravis.
    Koneczny I; Cossins J; Vincent A
    J Anat; 2014 Jan; 224(1):29-35. PubMed ID: 23458718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autoantibody Specificities in Myasthenia Gravis; Implications for Improved Diagnostics and Therapeutics.
    Lazaridis K; Tzartos SJ
    Front Immunol; 2020; 11():212. PubMed ID: 32117321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Longstanding and Refractory Anti-Muscle Specific Tyrosine Kinase Antibody-Associated Myasthenia Gravis (Anti-MuSK-MG) in a Child Successfully Treated with Rituximab.
    Weger S; Appendino JP; Clark IH
    J Binocul Vis Ocul Motil; 2019; 69(1):26-29. PubMed ID: 30811277
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies.
    Hoch W; McConville J; Helms S; Newsom-Davis J; Melms A; Vincent A
    Nat Med; 2001 Mar; 7(3):365-8. PubMed ID: 11231638
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.